SrasV1, 2020, Analysis, bibRecord, 000286

SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.

Identifieur interne : 000286 ( 2020/Analysis ); précédent : 000285; suivant : 000287

SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.

Auteurs : Michele Costanzo ; Maria Anna Rachele De Giglio ; Giovanni Nicola Roviello

Source :

Current medicinal chemistry [ 1875-533X ] ; 2020.

RBID : pubmed:32297571

Abstract

Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir (which is widely used to treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experimental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this virus. This also stresses the urgent need for the scientific community to devote its efforts to find other more specific antiviral strategies.

DOI: 10.2174/0929867327666200416131117
PubMed: 32297571

Affiliations:

Links to Exploration step

pubmed:32297571

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.</title>
<author><name sortKey="Costanzo, Michele" sort="Costanzo, Michele" uniqKey="Costanzo M" first="Michele" last="Costanzo">Michele Costanzo</name>
<affiliation><nlm:affiliation>Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples. Italy.</nlm:affiliation>
<wicri:noCountry code="subField">I-80131 Naples</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="De Giglio, Maria Anna Rachele" sort="De Giglio, Maria Anna Rachele" uniqKey="De Giglio M" first="Maria Anna Rachele" last="De Giglio">Maria Anna Rachele De Giglio</name>
<affiliation><nlm:affiliation>School of Medicine and Surgery, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples. Italy.</nlm:affiliation>
<wicri:noCountry code="subField">I-80131 Naples</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Roviello, Giovanni Nicola" sort="Roviello, Giovanni Nicola" uniqKey="Roviello G" first="Giovanni Nicola" last="Roviello">Giovanni Nicola Roviello</name>
<affiliation><nlm:affiliation>Istituto di Biostrutture e Bioimmagini IBB - CNR; Via Mezzocannone 16, I80134 Naples. Italy.</nlm:affiliation>
<wicri:noCountry code="subField">I80134 Naples</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32297571</idno>
<idno type="pmid">32297571</idno>
<idno type="doi">10.2174/0929867327666200416131117</idno>
<idno type="wicri:Area/PubMed/Corpus">000088</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000088</idno>
<idno type="wicri:Area/PubMed/Curation">000088</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000088</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000241</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000241</idno>
<idno type="wicri:Area/Ncbi/Merge">003B06</idno>
<idno type="wicri:Area/Ncbi/Curation">003B06</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003B06</idno>
<idno type="wicri:Area/Main/Merge">000286</idno>
<idno type="wicri:Area/Main/Curation">000286</idno>
<idno type="wicri:Area/Main/Exploration">000286</idno>
<idno type="wicri:Area/2020/Extraction">000286</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.</title>
<author><name sortKey="Costanzo, Michele" sort="Costanzo, Michele" uniqKey="Costanzo M" first="Michele" last="Costanzo">Michele Costanzo</name>
<affiliation><nlm:affiliation>Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples. Italy.</nlm:affiliation>
<wicri:noCountry code="subField">I-80131 Naples</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="De Giglio, Maria Anna Rachele" sort="De Giglio, Maria Anna Rachele" uniqKey="De Giglio M" first="Maria Anna Rachele" last="De Giglio">Maria Anna Rachele De Giglio</name>
<affiliation><nlm:affiliation>School of Medicine and Surgery, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples. Italy.</nlm:affiliation>
<wicri:noCountry code="subField">I-80131 Naples</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Roviello, Giovanni Nicola" sort="Roviello, Giovanni Nicola" uniqKey="Roviello G" first="Giovanni Nicola" last="Roviello">Giovanni Nicola Roviello</name>
<affiliation><nlm:affiliation>Istituto di Biostrutture e Bioimmagini IBB - CNR; Via Mezzocannone 16, I80134 Naples. Italy.</nlm:affiliation>
<wicri:noCountry code="subField">I80134 Naples</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">Current medicinal chemistry</title>
<idno type="eISSN">1875-533X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir (which is widely used to treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experimental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this virus. This also stresses the urgent need for the scientific community to devote its efforts to find other more specific antiviral strategies.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Costanzo, Michele" sort="Costanzo, Michele" uniqKey="Costanzo M" first="Michele" last="Costanzo">Michele Costanzo</name>
<name sortKey="De Giglio, Maria Anna Rachele" sort="De Giglio, Maria Anna Rachele" uniqKey="De Giglio M" first="Maria Anna Rachele" last="De Giglio">Maria Anna Rachele De Giglio</name>
<name sortKey="Roviello, Giovanni Nicola" sort="Roviello, Giovanni Nicola" uniqKey="Roviello G" first="Giovanni Nicola" last="Roviello">Giovanni Nicola Roviello</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000286 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000286 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32297571
   |texte=   SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32297571" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.

SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.